In CLL data from chromosome banding analysis (CBA) have been scarce due to the low proliferative activity of CLL cells in vitro. We improved the cultivation technique using an immunostimulatory CpG-oligonucleotide DSP30 and IL-2. A total of 506 CLL samples were analysed with CBA and interphase FISH using probes for the detection of trisomy 12, IgH rearrangements and deletions of 6q21, 11q22.3 (ATM), 13q14 (D13S25 and D13S319) and 17p13 (TP53). A total of 500 of 506 (98.8%) cases were successfully stimulated for metaphase generation and are subject to this study. Aberrations were detected in 415 of 500 (83.0%) cases by CBA and in 392 of 500 (78.4%) cases by FISH. CBA detected 832 abnormalities and FISH only 502. Therefore, CBA offers important information in addition to FISH. (1) CLL is characterized mainly by genomic imbalances and reciprocal translocations are rare. (2) A subgroup with complex aberrant karyotype (16.4%) is identified which is associated with an unmutated IgV H status and CD38 expression (P ¼ 0.034 and 0.02, respectively). (3) Additional abnormalities are detectable providing new biological insights into different CLL subclasses revealing a much more heterogeneous pattern of cytogenetic abnormalities as assumed so far based on FISH data only. Therefore, prospective clinical trials should evaluate the prognostic impact of newly available CBA data.
Introduction
The clinical heterogeneity of chronic lymphocytic leukemia (CLL) requires parameters to stratify patients into prognostic subgroups to adapt treatment ranging from 'watch and wait' to allogeneic stem cell transplantation. Different parameters such as clinical staging systems, lymphocyte doubling time, b-2 microglobulin, CD38 and ZAP70 expression, immunoglobulin variable heavy chain (IgV H ) mutation status and genetic abnormalities as determined by fluorescence in situ hybridization (FISH) have been integrated in clinical practice. 1, 2 Although the usefulness of chromosome banding analysis (CBA) for the classification and prognostication in other leukemias has been demonstrated, in CLL CBA data have been scarce due to the low proliferative activity in vitro even in the presence of B-cell mitogens. 3 Either no metaphases could be generated or clonal aberrations were detected in only 40-69% of cases, due to poor quality of the metaphases or the fact that only the normal hematopoietic cells were dividing in vitro. 4, 5 Therefore, studies using comparative genomic hybridization (CGH) and FISH on interphase nuclei have been performed as these techniques do not require proliferating cells. 6 Using FISH clonal aberrations were detected in more than 80% of CLL patients. 7 It was demonstrated that these aberrations are of prognostic impact. 8 Patients with 17p (7%) and 11q (17%) deletions had the shortest median survival, while deletions of 13q as the sole abnormality (36%) predicted a favorable outcome. 7, 8 However, CGH and FISH are hampered for several reasons: CGH only detects genomic imbalances and misses balanced translocations and the mechanism of gains and losses, interphase FISH is even more restricted as information is only available for the genes/loci for which probes were used. Therefore, for a comprehensive genetic analysis of CLL, CBA is warranted as it provides an overview of all microscopically visible chromosome abnormalities.
In previous studies, we demonstrated that the proliferation of CLL cells in vitro can be enhanced by the B-cell mitogen CD40-ligand (CD40L). CD40L-stimulation induced metaphases in 93% of cases vs 78% with conventional methods. 9 Even more importantly, CD40L-stimulation resulted in the detection of aberrations in 89% of cases vs only 22% by conventional cytogenetic techniques. 9 However, CD40L-enhanced cytogenetics is hardly applicable for routine diagnostics due to the need of a labor intensive, cellular co-culture system. Therefore, a different approach was taken by our group using a combination of an immunostimulatory CpG-oligonucleotide DSP30 and IL-2 that has already been reported to effectively induce cell cycle progression of CLL cells in vitro. 10 With this approach in our first preliminary study, 125 of 132 (94.7%) cases could be successfully stimulated for metaphase generation and 101 of 125 (80.8%) cases showed chromosomal aberrations. 11 Therefore, the objective of this study was to evaluate a large cohort of CLL to further analyse the additional information provided by CBA in comparison to interphase FISH. In addition, these data were correlated with the IgV H mutation status as well as CD38 and ZAP70 expression as measured immunophenotypically.
Materials and methods

Patients
After informed written consent was obtained, consecutive peripheral blood or bone marrow samples, which were referred to our laboratory since 1 August 2005, were analysed with CBA and interphase FISH. No case of this study had been included in our prior publication. 11 The requirement for entering this study was a confirmation of the diagnosis CLL based on immunophenotyping performed in our laboratory, where tumor cells expressed CD5, CD19 and CD23, but showed a weak expression of immunoglobulin (Ig) as well as of CD22 or CD79b. 12, 13 Metaphase cytogenetics Cultivation and chromosome preparation was done as described elsewhere. 11 For details see Supplementary Information. In each case of complex aberrations results of G-banding analysis were confirmed by 24-color FISH. 14 Chromosomes were classified according to the International System for Human Cytogenetic Nomenclature (ISCN 1995) . 15 Only clonal abnormalities according to ISCN definition are reported in this study. 15 Details on the scoring of abnormalities are provided in the Supplementary Material. A minimum of 15 metaphases had to be analysed in cases with normal karyotype. Cases with less than 15 normal metaphases were called not evaluable. In the 500 evaluable cases, a median of 20 metaphases was analysed per cases (range 5-30, mean 19.2).
Fluorescence in situ hybridization
Interphase FISH was done as described previously. 9, 16 The FISH included probes for the detection of trisomy 12, IgH rearrangements and deletions of 6q21, 11q22.3 (ATM), 13q14 (D13S25 and D13S319) and 17p13 (TP53). FISH for the detection of t(11;14)(q13;q32) was routinely done on all samples. Samples with t(14;18)(q32;q21) in metaphase cytogenetics were confirmed by FISH. Additional FISH probes for NMYC (2p24), BCL6 (3q27) and MYC (8q24) were used in a subgroup of patients to confirm abnormalities detected in CBA on interphases of uncultivated cells using peripheral blood or bone marrow smears.
Analysis of the IgV H status
IgVH status was analysed as previously described. 11 For details see Supplementary Material.
Immunophenotyping
Immunophenotyping was performed as described elsewhere applying four-color staining. 17 For details see Supplementary Material.
Statistics
Correlation analyses were done by w 2 -test or t-test. For statistical analysis SPSS (version 13.0) software (SPSS, Chicago, IL, USA) was used. Figure 1 and Supplementary Figures S1-S3 in the Supplementary Material were created by using CyDAS (http:// www.cydas.org/OnlineAnalysis/). 18 
Results
Patient characteristics
A total of 506 CLL were analysed in parallel with CBA and interphase FISH. A total of 500 cases with evaluable metaphase cytogenetics are subject to this study. A total of 179 females (35.8%) and 321 males (64.2%) with a median age of 66.3 years (range: 30.9-85.6 years) were included. Data on clinical stage are provided in Table S1 in the Supplementary Material. Prior treatment in patients who were analysed during the course of their disease was very heterogeneous including treatment with chlorambucil, fludarabine, CHOP and bendamustine.
Chromosome banding analysis
A total of 500 of 506 (98.8%) cases could be successfully stimulated for metaphase generation and allowed karyotyping of at least 5 metaphases, in median 20 metaphases were analysed as recommended in a European consensus protocol. 19 These 500 cases were further studied. A total of 415 of 500 (83.0%) cases showed chromosomal aberrations in metaphase cytogenetics. Overall 832 abnormalities were detected by CBA. In CBA only one aberration was detected in 191 cases, 2 in 119, 3 in 49, 4 in 24 and 5 or more aberrations in 32 patients, respectively. The median number of aberrations was one per case (range 0-10), the mean number 1.7.
Gains and losses of chromosomal material as observed in the total cohort by CBA are depicted in Figure 1 .
Reciprocal translocations in CLL. The incidence of reciprocal translocations in CLL is 19.8% (99 of 500 cases). In detail, translocations involving the IgH gene on 14q32 were observed in 27 cases (5.4%). The recurring partner genes were 11q13 (n ¼ 11), 18q21 (n ¼ 7) and 19q13 (n ¼ 3). The remaining six were non-recurrent and located in 2p13, 4p16, 4q31, 5q31, 8q11 and 9q34, respectively. The other two loci coding for the light chains located at 2p11 and 22q11 were involved in 1 and 3 translocations, respectively. The partner gene in these four cases was BCL2 located on 18q21 as confirmed by FISH. In 4 of these 31 cases the Ig translocation was the sole abnormality, in 15 cases 1 additional abnormality, in 4 cases 2 additional abnormalities and in 2 cases each 3, 4, and 5 additional abnormalities were observed, respectively. One case each showed 6 and 7 additional abnormalities, respectively. Recurring additional aberrations were trisomy 12 (n ¼ 11), deletion 13q (n ¼ 7), loss of 17p (n ¼ 4), loss of 8p (n ¼ 3), trisomy 3 (n ¼ 3), loss of 16p (n ¼ 2), loss of the X-chromosome (n ¼ 2) and loss of the Y-chromosome (n ¼ 2).
The pattern of chromosomal gains and losses in CLL showing a translocation with involvement of an Ig locus ( Figure S1 , Supplementary Material) was compared to the pattern of aberrations observed in CLL cases without a complex aberrant karyotype and without an Ig translocation (Supplementary Figure S2 , Supplementary Material). It was observed that gains of 3q and loss of 8p were only present in the group with Ig translocation.
Furthermore, 38 reciprocal translocations were observed that involved 13q14 (7.6%). The breakpoints on the partner chromosomes and more details on this subgroup are listed and depicted in Supplementary Figure S4 in the Supplementary Material. Interphase FISH demonstrated a 13q14 deletion in 36 of these cases. Therefore, metaphase FISH was performed with a whole-chromosome painting probe for chromosome 13 and a probe for the locus D13S25 or D13S319, respectively, on metaphases. These analyses confirmed a loss of 13q material within the breakpoint region in all 36 cases.
In addition, in the total cohort 30 other reciprocal translocations were observed. However, none of these was recurring.
Numerical aberrations. Trisomy 12 was the most frequent numerical abnormality and was observed in 68 cases (13.6%). Further recurrent trisomies were of chromosomes 3 (n ¼ 3), 18 (n ¼ 6), and 19 (n ¼ 11). The most frequent chromosomes lost were X (n ¼ 9) and Y (n ¼ 13). Recurrent losses were found also for chromosomes 4 (n ¼ 2), 8 (n ¼ 2), 15 (n ¼ 5), 17 (n ¼ 4) and 18 (n ¼ 2).
Structural unbalanced abnormalities leading to gain and/or loss of genetic material. The most frequent structural aberrations leading to loss of genetic material were a partial loss of the long arm of chromosome 13 (n ¼ 274) and of the long arm of chromosome 11 (n ¼ 60).
Further details on aberrations are provided in the Supplementary Material. 
Interphase-FISH analysis
All 500 cases were successfully analysed by interphase FISH revealing at least one abnormality in 392 patients (78.4%). These were deletions of chromosomes 13q (n ¼ 287, 57.4%; in n ¼ 215, 43% as sole abnormality; in n ¼ 77, 15.4% a homozygous deletion was detected), 11q (n ¼ 60, 12%; as the sole abnormality n ¼ 23, 4.6%), trisomy 12 (n ¼ 68, 13.6%; as the sole abnormality n ¼ 38, 7.6%), 6q (n ¼ 23, 4.6%; as the sole abnormality n ¼ 10, 2.0%), 17p (n ¼ 35, 7.0%, as the sole abnormality n ¼ 8, 1.6%) and translocations involving 14q32 (n ¼ 30, 6.0%; as the sole abnormality n ¼ 13, 2.6%) ( Table 1) .
Comparison of FISH and chromosome banding analysis
Overall 415 cases (83%) showed an aberrant karyotype in CBA, while in comparison at least one abnormality was detected by FISH in 392 patients (78.4%). By FISH 302 (60.4%) of cases showed a single aberration, 74 (14.8%) two aberrations, 12 (2.4%) three aberrations and 4 (0.8%) four aberrations. In metaphase cytogenetics, one aberration was detected in 191, two in 119, three in 49, four in 24 and five or more aberrations in 32 patients ( Figure 2 ).
CBA detected abnormalities in 34 of 108 (31.5%) cases showing no aberrations in FISH. All these abnormalities could not be detected by FISH, because they were not covered by the standard FISH panel. On the other hand, 11 of 85 cases (12.9%) with a normal karyotype demonstrated abnormalities using FISH. These were 13q deletions in eight cases and t(11;14)(q13;q32) in three cases, respectively. In three of these cases (all with t(11;14)(q13;q32)), the abnormality was not detected by CBA because of the small clone size (3, 7 and 10% of aberrant interphase nuclei in FISH, respectively) or a low proliferative activity in vitro (three cases with 13q-deletion). In five cases showing a 13q14 deletion in interphase FISH, the same aberration could also be demonstrated on metaphases by FISH. However, the deletion was too small to be seen by CBA (that is, cryptic 13q-deletion).
In conclusion, cytogenetic aberrations were detected in 426 of 500 (85.2%) cases either by metaphase cytogenetics and/or interphase FISH.
The absolute number of aberrations detected by chromosome analysis overall was 832 as compared to 502 aberrations detected by FISH.
In 135 cases more than one aberrant clone was detected by CBA. A total of 125 cases showed clonal evolution and in 10 (2%) cytogenetically independent subclones were observed (Supplementary Material Table S2 , Supplementary Figure S5 ).
CLL with 13q14 deletions
Overall, in 287 cases, a 13q14 deletion was detected by interphase FISH. Based on FISH results, the 13q14 deletion was the sole abnormality detected in 215 cases. In 77 cases, a homozygous 13q14 deletion was observed. With respect to aberrations occurring in addition to 13q-deletions a negative correlation was observed with trisomy 12 (Po0.0001) and translocations involving 14q32 (P ¼ 0.0003). 
Genetic Characterization of CLL C Haferlach et al
Deletions of 13q were detected in 243 cases affecting both chromosome 13 in 31 cases. Therefore, the deletion of one chromosome 13 was cryptic in 46 cases with homozygous 13q14 deletion as determined by FISH on interphase nuclei and/ or metaphases. Overall in eight cases showing loss of 13q14 by interphase FISH this was not detectable by CBA due to low proliferative activity in vitro in three cases and due to the small size of the deletion in five cases. In 36 cases metaphase cytogenetics revealed that 13q14 loss occurred in combination with a reciprocal translocation. With respect to additional chromosomal aberrations, CBA revealed that only in 134 cases the 13q aberrations was the sole abnormality, in 117 cases due to an interstitial deletion and in 17 cases due to translocation. A 13q deletion/translocation occurred in 53 cases within a complex aberrant karyotype, in 7 cases in addition to a translocation involving an Ig locus.
Thus, based on CBA cases with 13q deletion could be subdivided into four different categories: (1) del(13q) sole, (2) del(13q) with additional abnormalities and (3) del(13q) in combination with a reciprocal translocation, (4) submicroscopic and therefore cytogenetically not visible 13q14 deletions, detectable only by FISH.
CLL with 11q deletions
Overall, in 60 cases an 11q22.3 deletion was detected in interphase FISH. In 56 of these 60 cases, an interstitial or terminal 11q deletion was observed in metaphase cytogenetics while loss of 11q22.3 was due to an unbalanced translocation in four cases. Only in 13 cases (21.7%) the 11q deletion was the sole abnormality detected by CBA. An 11q deletion occurred in 21 cases within a complex aberrant karyotype, and in 11 cases in addition to a translocation involving an Ig locus. The most frequent abnormality observed in addition to 11q deletion was a deletion of the long arm of chromosome 13 (n ¼ 35) (Table 1) .
CLL with trisomy 12
Overall, in 68 cases a trisomy 12 was detected in interphase FISH, in 38 cases as the sole abnormality. However, only in 20 of these cases no additional aberrations were detected by CBA. A trisomy 12 occurred in 16 cases within a complex aberrant karyotype, and in 11 cases in addition to a translocation involving an Ig locus. The most frequent abnormalities observed in addition to trisomy 12 were a deletion of the long arm of chromosome 13 (n ¼ 20), trisomy 19 (n ¼ 11), loss of 17p (n ¼ 6), trisomy 18 (n ¼ 5), a deletion of the long arm of chromosome 11 (n ¼ 3) and a deletion of the long arm of chromosome 14 (n ¼ 3).
With respect to aberrations occurring in addition to trisomy 12 a positive correlation was detected with t(14q32) (P ¼ 0.01) and a negative correlation with deletion 13q (Po0.0001).
CLL with 6q deletion
Overall, in 23 cases a 6q21 deletion was detected in interphase FISH. The most frequent abnormalities observed in addition to the 6q deletion were a deletion of the long arm of chromosome 13 (n ¼ 8), and a loss of 17p (n ¼ 5). In two additional cases, a 6q deletion not involving 6q21 was observed in CBA. In nine cases no further abnormalities were observed in addition to the 6q in metaphase cytogenetics. Loss of 6q occurred due to deletions 20 times and due to unbalanced translocations 6 times.
With respect to aberrations occurring in addition to 6q deletion a positive correlation was detected with 17p deletion (P ¼ 0.005).
TP53 deletions/17p abnormalities
Overall, in 35 cases (7%), a TP53 deletion was detected in interphase FISH. Loss of 17p occurred due to monosomy 17 4 times, due to deletion 17p 6 times, due to an isochromosomes 17q 4 times and due to unbalanced rearrangements 23 times. A 17p deletion occurred in 23 cases with a complex aberrant karyotype, in seven cases in addition to a translocation involving an Ig locus. With respect to aberrations occurring in addition to loss of 17p a positive correlation was detected with 6q deletion (P ¼ 0.005) and with translocations involving 14q32 (P ¼ 0.0004). In cases with 17p abnormalities showing a TP53 deletion, the number of chromosome abnormalities was higher compared to cases without TP53 deletion (mean 5.0 vs 1.5, Po0.0001) (Figure 3 (Tables 2 and 3 ).
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Correlation of the CD38 expression with cytogenetic aberrations
CD38 expression is an independent prognostic marker in CLL. 20 In most studies, a cutoff of X30% CD38 positive cells in flow cytometry describes a CD38 positive status, which is associated with an unfavorable clinical course. 20 In this study, CD38 expression was available in 369 of 500 patients (73.8%). A total of 188 of the samples were characterized by o30% CD38 expression, while 181 samples were CD38 positive (i.e., X30%). A CD38 expression significantly correlated with the IgV H status (Po0.0001), as 100 CD38 þ cases showed an unmutated IgV H , while 61 cases of the CD38 þ had a mutated IgV H . On the other hand more cases of the CD38 negative group demonstrated a mutated IgV H status (114/163). A CD38 expression significantly correlated to an 11q deletion (P ¼ 0.0003), trisomy 12 (o0.0001), IgH rearrangement (P ¼ 0.027) and a complex aberrant karyotype (P ¼ 0.02). On the other hand, a low CD38 expression was correlated to 13q deletions (Po0.0001) ( Tables 4 and 5 ).
ZAP70 expression
ZAP70 expression is used as a surrogate marker for the IgV H status in CLL. 21 In most studies, a cutoff of X20% ZAP70 positive cells in flow cytometry describes a ZAP70 positive status, which is associated with unfavorable clinical course. 22, 23 In this study, ZAP70 expression was available in 432 of 500 patients (86.4%). A total of 110 of the samples showed o20% ZAP70 expression, while 322 samples were ZAP70 positive. 
Cases with t(11;14) or t(14;18)
A total of 14 cases had t(11;14) and 7 cases had t(14;18). All of them displayed an immunophenotype yielding a score of four or five according to Matutes. 12 While, in general, the application of the Matutes score results in a high degree of concordance between different methods applied in the diagnostic setting of CLL, the above cases should be considered atypical but nevertheless fulfill the standard criteria of CLL and do not show any other differences within the whole cohort investigated here.
Discussion
CBA has provided important information with respect to biology and prognosis in several hematologic malignancies. One of the major advantages of CBA as compared to other techniques performed to characterize genetic abnormalities in malignancies is the derivation of an overview of all microscopically visible aberrations without previous knowledge of affected regions. However, CBA requires cell division in vitro. CLL cells show a low mitotic index in vitro, 3 and therefore in the past failure rate of CBA was high and the proportion of cases showing chromosome aberrations was low. 4 This problem was overcome by adding DSP30 plus interleukin-2 to the culture medium resulting in a high success and aberration rate. 11 However, prior to these very recent improvements in culture techniques, the genetic characterization of CLL was based mostly on FISH on interphase nuclei, because this technique does not depend on cell division in vitro. In order to characterize CLL by FISH analysis probes for the detection of trisomy 12, deletions of 6q21, 11q22.3, 13q14 and 17p13 are used. 7, 24, 25 With this approach aberrations are detected in about 80% of CLL samples. 7, 24, 25 In our pilot study, we successfully performed CBA in 125 of 132 (94.7%) CLL cases, revealing an aberrant karyotype in 101 of 125 cases (80.8%), which is an almost 2-fold increase to earlier chromosomal banding studies and comparable to the aberration rate detected by FISH analyses. 11 Only the use of CD40-ligand as a B-cell stimulus in two other studies produced comparable results with respect to metaphase generation and chromosomal aberrations. 9, 26 Potentially, in vitro stimulation using CD40-ligand, DSP30 and IL-2 or any other stimulant can introduce a selection bias. However, the benefit of receiving aberrant metaphases at all outweighs a potential shift between different aberrant clones and the normal clone. If the size of clones carrying a specific abnormality seems to be important, suitable FISH probes can be selected according to the abnormalities detected by CBA.
Our first study revealed that CBA provided interesting additional information indicating that FISH analysis underestimates the complexity and heterogeneity of chromosomal aberrations in CLL.
11 Therefore, we started this prospective study to elucidate the value of CBA in CLL in a cohort of another 506 patients. CBA proved to be a very robust technique, if samples arrive within 48 h after extraction. In 98.8% of examined cases, sufficient metaphases were obtained to receive a reliable result on the karyotype.
Overall, CLL is characterized mainly by genomic imbalances affecting loss of 13q, 11q, 6q and 17p as well as gain of chromosome 12 with none of these genetic aberrations being mutually exclusive. In this study, we confirmed that the number of aberrations detected by CBA exceeds the number of aberrations detected by the standard FISH panel (832 vs 502). However, the most frequent aberrations observed in CBA were covered by the FISH panel confirming the high value of the latter method. Yet, CBA provided relevant additional information. Based on karyotype data cases with 13q deletion could be subdivided on one hand based on the mechanism leading to 13q loss (interstitial deletion vs reciprocal translocation) and on the other hand based on the number of additional aberrations. While based on FISH results, 215 patients would have been assigned to the prognostically most favorable group with 13q deletions as the 'sole abnormality', CBA demonstrated additional abnormalities in 73 (34%) of these cases. The clinical relevance of this finding has to be further analysed within prospective trials. First, evidence for the hypothesis of a less favorable outcome is provided in a small study on 43 patients with 13q deletion, detected as single aberration in interphase FISH. A total of 11 of these patients showed additional aberrations in CBA. These patients had a significantly shorter Table 5 Correlation of CD38 expression to cytogenetic subgroups in 369 patients with CLL Genetic Characterization of CLL C Haferlach et al median treatment-free survival (TFS) of 41 months as compared to patients with 13q deletion as sole aberration as determined by CBA who had a median TFS of 132 months. 26 In a recently published study on 65 CLL patients treated with cladribine patients with unbalanced translocations displayed a shorter median TFS (6.9 vs 35.9 months, log rank 22.72, Po0.001) and overall survival (OS, 13.0 vs 68.0 months, log rank 16.51, Po0.001), as compared to patients without translocation. In multivariate analysis, unbalanced translocations were independently associated with therapeutic failure, short TFS and short OS. 27 Furthermore varying sizes of deletion of 13q as well as of 6q and 11q were identified by CBA and are not detectable by the standard FISH panel. Whether these deletion sizes may have any impact on prognosis has also to be further evaluated.
We further confirmed data that various aberrations detected by FISH are significantly different distributed within the IgV H mutated and unmutated cases of CLL 28 : the poor prognostic marker del(11q) is clearly overrepresented in patients with unmutated IgV H (Po0.0001) compared to the good prognosis del(13q) as sole abnormality with an overrepresentation in the mutated IgV H group (Po0.0001). In addition, 6q deletions, 17p deletions and trisomy 12 as the sole abnormality were significantly more frequent in patients with unmutated IgV H (P ¼ 0.001, 0.003 and 0.015, respectively). Furthermore, a significant association between a complex aberrant karyotype determined by CBA and an unmutated IgV H was observed (P ¼ 0.034).
We further found a positive CD38 expression status being significantly associated with 11q deletion and trisomy 12, respectively, as already has been reported by others. 29 In addition, we observed also a significant association of positive CD38 expression status with IgH rearrangement and a complex aberrant karyotype, respectively, while a negative CD38 expression status was significantly associated with 13q deletion. In contrast to others, we did not observe an association between CD38 expression and 17p deletion. 29 The less stronger correlation of cytogenetics to the expression of ZAP70 may be in part due to the issue of determining the most appropriate way of analysis which is still under discussion. 30 Thus, qualitative differences have been demonstrated among five different antibodies against ZAP70. 31 Accordingly, we found better correlations with the IgV H mutation status for the SBZAP antibody as compared to the 1E7.2 antibody which has been used in the present study. 32 Previous studies demonstrated that the complexity of the karyotype was prognostically important in CLL, that is, patients with increasing numbers of clonal abnormalities were found to have a progressively shorter survival. 4, 26, 33, 34 We defined a karyotype as complex aberrant if three or more clonal aberrations were present corresponding to the definition in other hematological malignancies and the cited studies in CLL. 4, [33] [34] [35] [36] [37] [38] Based on FISH data, only 16 cases (3.2%) were identified as complex aberrant karyotype, while 105 cases (21%) showed a complex aberrant karyotype based on CBA. In mean 4.26 aberrations were detected per case (range 3-10). Interestingly, comparable to acute myeloid leukemia (AML) 14, 37 also in CLL, we observed an association between TP53 deletion and the number of chromosome aberrations. In addition, patients with a complex aberrant karyotype were more likely to show an unmutated IgV H status (P ¼ 0.034) and a positive CD38 expression status (P ¼ 0.02).
CBA revealed that several genetic aberrations do occur as the sole cytogenetic abnormality such as deletions 6q, 11q and 13q, and trisomy 12. However, they occur also in combination with each other. No evidence of a hierarchy of these abnormalities was found with one of these being more likely the primary aberration followed by one or several of the others. It therefore appears that overlapping pathways of genetic aberrations exist in CLL. However, our data suggest that some abnormalities are likely to be secondary changes such as gain of 2p, 3q and 8q as well as loss of 8p as these were never observed as the sole abnormality and were only found within complex aberrant karyotypes. Gain of 2p has been recently recognized as a recurrent aberration in CLL by SNP array analysis in 4 of 70 cases (5.7%) and a common minimal 3.5 Mb gain of 2p16 spanning the REL and BCL11A oncogenes identified. 39 In our cohort 13 cases (2.6%) showed a gain of 2p, all included chromosomal band 2p16.
In contrast to mantle cell and follicular lymphoma which demonstrate t(11;14)(q13;q32)/IgH-CCND1 rearrangements and t(14;18)(q32;q21)/IgH-BCL2 rearrangement in the majority of cases, rearrangements involving the Ig loci are rare in CLL and were observed in only 6.8% of cases. The partner genes were heterogeneous and the most frequent ones were CCND1 and BCL2. CLL cases carrying t(11;14)(q13;q32) or t(14;18)(q32;q21) have been published as rare findings. 7, 17, [40] [41] [42] [43] In our cohort, we identified 14 patients with t(11;14)(q13;q32) and seven cases with t(14;18)(q32;q21) all with typical immunophenotype of B-CLL. These specific subgroups of patients should be followed clinically and analysed with other biological makers in more detail in order to clarify whether they are closer related to CLL or mantle cell lymphoma or follicular lymphoma, respectively. Vizcarra et al. 44 provided already first evidence that a specific subtype of B-lymphoproliferative disease exists, which shows a t(11;14)(q13;q32)/IgH-CCND1 rearrangement with a clinical presentation indistinguishable from CLL and is characterized by gains of 3q, 8q and 15q as well as loss of 6q, 9p, 13q and 17p. All these imbalances with exception of 9p loss were also detected in our cohort of CLL patients with t (11;14) .
Our data reveal that reciprocal translocations are rare but unbalanced non-reciprocal translocations leading to gains or more often losses usually of larger parts of chromosomes are frequent in CLL, again underlining the relevance of gene dosage changes in CLL. It has already been demonstrated by gene expression analysis that loss of 11q22-q23 and 17p translates into reduced expression of genes located in these regions and that gain of chromosome 12 is associated with an increased expression of genes mapping to 12q. 45 In conclusion, our data confirm that DSP30 in combination with IL-2 is an easy and efficient stimulus for metaphase generation in CLL. This technique for the first time allows a more comprehensive chromosome analysis providing information on the whole genome and resulted in the detection of additional aberrations compared to FISH and the identification of a subgroup with a complex aberrant karyotype, which is correlated to other negative prognostic parameters such as TP53 deletion, an unmutated IgV H status and a positive CD38 expression status. While our previous study demonstrated the feasibility of CBA in a routine setting with a high success and aberration rate, this study provides due to a higher number of patients a representative pattern of cytogenetic aberrations in CLL comprising also rare abnormalities.
Our data further suggest that CBA may provide additional prognostic information in CLL. As response to different types of treatment varies according to genetic abnormalities, 8, [46] [47] [48] future prospective clinical trials in CLL should urgently test the prognostic value of CBA in direct comparison to FISH, IgVH status, ZAP70 and CD38 expression. These trials should also clarify which combination of techniques is necessary for the most accurate risk assignment in order to propose a costeffective strategy for routine diagnostics. CBA provide more information and could be less expensive than FISH, if a large panel of FISH probes turns out to be necessary for exact risk stratification especially with respect to new treatment options. In addition, efforts have to be undertaken to apply explorative statistics using all available clinical data together with information about genome-wide genetic aberrations in order to identify poor-risk CLL patients that should undergo experimental treatments (for example, allogeneic stem cell transplantation).
